Research institution
Institute of Hematology & Blood Diseases Hospital, China Clinical Trials
Studies where Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 250Aplastic Anemia, Refractory
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
This study consists of two phases, phase Ib and phase II. The primary objective of phase Ib is to evaluate the safety and tolerability of multiple doses of daratumumab in patients with refractory aplastic anemia.
- Conditions
- Aplastic Anemia, Refractory, Relapse
- Trial name
- DARA-AA-001 (NCT07287228)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALL
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL
This prospective, open-label, single-arm study evaluates whether reduced-intensity induction with venetoclax plus inotuzumab ozogamicin (2VIP) followed by one cycle of blinatumomab improves the 8-week NGS-MRD-negative complete…
- Trial name
- ALL-CD22-Ph (NCT07921550)
- Testing
- Inotuzumab ozogamicin (INO), Venetoclax (VEN), Vincristine
- Volunteers
- 43 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Plasmablastic Lymphoma
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study
This is a single-center, single-arm, open-label, phase II exploratory clinical study designed to evaluate the efficacy and safety of QLS4131 combined with the Isa-V-CHOP regimen in patients with treatment-naive, HIV-negative…
- Trial name
- PBL-001 (NCT07921615)
- Testing
- QLS4131 combined with Isa-V-CHOP
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Measurable Residual Disease, Acute Myeloid Leukemia
Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT
To assess the value of deep NGS-MRD detection for risk stratification in adult high-risk acute myeloid leukemia (AML) patients, in this prospective, single-center, observational cohort study following allogeneic hematopoietic…
- Trial name
- NCT07919119
- Testing
- NGS-MRD AML cohort
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Autoimmune Hemolytic Anemia, Relapsed/Refractory
IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection (In Vivo CAR-T) in Patients with Relapsed/Refractory Autoimmune…
- Trial name
- NCT07585071
- Testing
- IASO206 injection
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Leukemia
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
- Trial name
- CAREMM-002 (NCT05979363)
- Testing
- anti-BCMA CAR-T, VRD-based regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Autoimmune Hemolytic Anemia
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
This is an open-label, phase I clinical study of F182112 in patients with relapsed or refractory autoimmune hemolytic anemia (AIHA). Participants will receive F182112 at different dose levels.
- Trial name
- NCT07816341
- Testing
- F182112 single-agent
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
CAR T-cell Therapy, Autoimmune Hemolytic Anemia
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other…
- Conditions
- CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being
- Trial name
- NCT06921980
- Testing
- Brain function and psychological assessment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Large Granular Lymphocyte Leukemia, T-LGL Leukemia
A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
This study is a single-arm, prospective, exploratory clinical trial aimed at exploring the efficacy and safety of zeprumetostat in patients with relapsed/refractory large granular T-cell leukemia.
- Trial name
- NCT07692529
- Testing
- zeprumetostat
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Transfusion-dependent Beta-Thalassemia, Gene Therapy
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who…
- Trial name
- NCT05991336
- Testing
- Gene therapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China